Eveliqure announces regulatory approval to commence first clinical studies with its combined Shigella and ETEC vaccine

04 Jun'20

Eveliqure Biotechnologies has announced that the Hungarian regulatory agency OGYÈI has approved the clinical trial for its vaccine program to prevent diarrhoeal diseases caused by Shigella and Enterotoxigenic E.coli (ETEC).

Diarrhoeal diseases are the most common illnesses in the world today, with an estimated 1.7B cases annually. Affecting 30-50% of travellers visiting developing countries, this is typically considered a non-life-threatening inconvenience, but diarrhoeal diseases kill over 2000 children every day in low- and middle- income countries. Vaccines have been successfully developed for diarrhoeal disease caused by cholera, typhoid and rotavirus. Shigella and Enterotoxigenic E. coli (ETEC) accounts for up to 50% of all diarrhoea cases, but no effective vaccines exist. In response to this, Eveliqure has developed ShigETEC, the only vaccine close to clinical testing that targets both these major bacterial pathogens.

Back